{"entity":{"id":"idp-001","kind":"drug","name":"IDP-001","aka":[],"tldr":"IDP-001 is an experimental bispecific antibody-drug conjugate from InduPro Therapeutics, in phase 1 trials for non-small cell lung cancer, head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma and other cancers.","summary":"IDP-001 is a bispecific antibody-drug conjugate from InduPro Therapeutics. A proximity-based bispecific antibody-drug conjugate designed to target both EGFR and a novel tumour-associated antigen whose name the company has blinded (TAPA-E1). The company says dual targeting enhances tumour selectivity, target internalisation and efficacy. Its furthest stage is phase 1, for non-small cell lung cancer (squamous and non-squamous), head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma and cervical squamous cell carcinoma. ClinicalTrials.gov registers it in one study linked below. First patient dosed in phase 1, announced 12 August 2026; NCT07602842 recruiting (registry lists phase 1/2). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"InduPro Therapeutics: induprotx.com","url":"https://www.induprotx.com/pipeline"},{"label":"InduPro Therapeutics: induprotx.com","url":"https://www.induprotx.com/news/indupro-closes-77-million-series-b-financing-and-doses-first-patient-in-phase-1-study-of-lead-oncology-program-idp-001/"},{"label":"InduPro Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07602842"},{"label":"ClinicalTrials.gov: trials of IDP-001","url":"https://clinicaltrials.gov/search?intr=IDP-001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","head-and-neck","cutaneous-scc","cervical","oesophageal-squamous-cell-carcinoma","anal"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":["indupro-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07602842"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"IDP-001","modality":"Bispecific antibody-drug conjugate","mechanism":"A proximity-based bispecific antibody-drug conjugate designed to target both EGFR and a novel tumour-associated antigen whose name the company has blinded (TAPA-E1). The company says dual targeting enhances tumour selectivity, target internalisation and efficacy.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/idp-001/","neighbours":{"cancer":[{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"company":[{"id":"indupro-therapeutics","kind":"company","name":"InduPro Therapeutics","route":"/companies/indupro-therapeutics/"}],"trial":[{"id":"nct07602842","kind":"trial","name":"A Study of IDP-001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct07602842/"}]}}